ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2007
Recent developments in cell-based immune therapy for neuroblastoma.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model.Experimental and therapeutic medicine · 2014Article
- Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.British journal of cancer · 2010Article
- NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors.Cancer gene therapy · 2009Article
- Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.Current pharmaceutical design · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, gammadelta T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.
Indexed as
Identifiers
18040838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.